Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial

SIMPLE SUMMARY: We recently published the results of the AVASTEM study, in which we explored the impact of the addition of an angiogenesis inhibitor (bevacizumab) to standard pre-operative chemotherapy for breast cancer. In this work, we aimed to identify biological parameters correlated to prognosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabatier, Renaud, Pierga, Jean-Yves, Curé, Hervé, Abulnaja, Rakan, Lambaudie, Eric, Bidard, François-Clément, Extra, Jean-Marc, Sfumato, Patrick, Gonçalves, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796232/
https://www.ncbi.nlm.nih.gov/pubmed/33466225
http://dx.doi.org/10.3390/cancers13010140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796232/
https://www.ncbi.nlm.nih.gov/pubmed/33466225
http://dx.doi.org/10.3390/cancers13010140

Ejemplares similares